EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lipid Nanoparticle Co‐Delivery of mRNA and a Small Molecule Drug for Oral Cancer Chemoimmunotherapy

Marshall S Padilla iD, Jacqueline J Li, Qunzhou Zhang iD, Korey Patwari, Shihong Shi, Hannah M Yamagata, Ryann A Joseph, Briyanna N Hymms, Sridatta V Teerdhala, Emily Fitzgerald, Ori Z Chalom, Kushol Gupta und 4 weitere

Advanced Materials · 2026-08 · 38 (47)

DOI: 10.1002/adma.73721 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 14.07.2026. Verfasst von Marshall S Padilla und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Mouth Neoplasms, Nanoparticles, RNA, Messenger, Lipids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH High-End Instrumentation, NIDCR NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral squamous cell carcinoma (OSCC) represents 90% of all head and neck cancers. Despite decades of research, the 5‐year survival rate is 50%. Strikingly, the overall incidence rate is projected to increase by 30% in the next 10 years, which may result in a sharp increase in mortality. Two fundamental aspects of OSCC are that it progresses via the inactivation and mutation of tumor suppressor genes (TSGs) and has a “cold” tumor microenvironment (TME). A major barrier in the treatment of OSCC is the lack of novel therapies clinicians have at their disposal that are designed to disrupt tumor progression by reshaping the cold tumors into inflammatory “hot” tumors. To overcome these obstacles, we employed a lipid nanoparticle (LNP) that co‐encapsulates p53 mRNA and the small molecule ciclopirox (CPX). We demonstrate that both drugs have innate chemotherapeutic properties by facilitating caspase activation. Moreover, these therapies can create a less immunosuppressive TME in part by repolarizing tumor‐associated macrophages (TAMs) to M1‐like phenotypes. When formulated together, our platform provides an all‐in‐one approach for OSCC, effective in both p53‐therapy‐susceptible and p53‐therapy‐resistant models. Additionally, this work offers a template for a delivery platform capable of tackling multiple mechanisms of OSCC progression and survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mouth NeoplasmsNanoparticlesRNA, MessengerLipidsImmunotherapyAntineoplastic AgentsPyridonesDrug CarriersTumor Suppressor Protein p53AnimalsHumansCell Line, TumorTumor MicroenvironmentCarcinoma, Squamous CellMiceTumor-Associated MacrophagesLiposomes

Stichwörter der Autor:innen

lipid nanoparticlesmRNA therapyoral squamous cell carcinomatumor‐associated macrophages

Substanzen

RNA, MessengerTumor Suppressor Protein p53LipidsAntineoplastic AgentsPyridonesLipid NanoparticlesDrug CarriersLiposomes

Autor:innen und Institutionen

  • Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Oral and Maxillofacial Surgery and Pharmacology, University of Pennsylvania School of Dental Medicine, Philadelphia, Pennsylvania, USA.
  • Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Penn Institute for RNA Innovation, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Oral & Maxillofacial Surgery, Penn Medicine Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Marshall S Padilla, Qunzhou Zhang, Mohamad-Gabriel Alameh, Drew Weissman

Förderung

  • NIH High-End Instrumentation
  • NIDCR NIH HHS
  • NIH HHS
  • NIH/NIDCR: R01 DE031023
  • Johnson Foundation Structural Biology and Biophysics Core
  • Center for Innovation & Precision Dentistry (CiPD) at the University of Pennsylvania
  • University of Pennsylvania

Zitieren

APA

Padilla, M. S., Li, J. J., Zhang, Q., Patwari, K., Shi, S., Yamagata, H. M., Joseph, R. A., Hymms, B. N., Teerdhala, S. V., Fitzgerald, E., Chalom, O. Z., Gupta, K., Alameh, M. G., Weissman, D., Le, A. D., & Mitchell, M. J. (2026). Lipid Nanoparticle Co‐Delivery of mRNA and a Small Molecule Drug for Oral Cancer Chemoimmunotherapy. Advanced Materials, 38(47). https://doi.org/10.1002/adma.73721

Vancouver

Padilla MS, Li JJ, Zhang Q, Patwari K, Shi S, Yamagata HM, et al. Lipid Nanoparticle Co‐Delivery of mRNA and a Small Molecule Drug for Oral Cancer Chemoimmunotherapy. Advanced Materials. 2026;38(47). doi:10.1002/adma.73721

BibTeX
@article{Padilla2026,
  author = {Padilla, Marshall S and Li, Jacqueline J and Zhang, Qunzhou and Patwari, Korey and Shi, Shihong and Yamagata, Hannah M and Joseph, Ryann A and Hymms, Briyanna N and Teerdhala, Sridatta V and Fitzgerald, Emily and Chalom, Ori Z and Gupta, Kushol and Alameh, Mohamad-Gabriel and Weissman, Drew and Le, Anh D and Mitchell, Michael J},
  title = {Lipid Nanoparticle Co‐Delivery of mRNA and a Small Molecule Drug for Oral Cancer Chemoimmunotherapy},
  journal = {Advanced Materials},
  year = {2026},
  volume = {38},
  number = {47},
  doi = {10.1002/adma.73721}
}
Kostenlos starten →